Although IL-27 efficiently suppressed tumor growth and progression in tumor-bearing animals, clinical use of recombinant IL-27 is limited by the fact that continuous delivery of IL-27 may generate strong systemic T cell-driven immune response which could result in the development of life-threatening cytokine storm [19]. The gene discussed is IL27; the disease is neoplasm.